ACL
Arcellx
Stock
Stock
Ticker: ACLX
ACLX
Price
Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for Arcellx?
Arcellx's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -4.055. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Arcellx's stock?
Currently, 1 analysts cover Arcellx's stock, with a consensus target price of $115.00. Analyst ratings provide insights into the stock's expected performance.
What is Arcellx's revenue over the trailing twelve months?
Over the trailing twelve months, Arcellx reported a revenue of $22.29M.
What is the EBITDA for Arcellx?
Arcellx's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$246.41M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Arcellx?
Arcellx has a free cash flow of -$212.59M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Arcellx have, and what sector and industry does it belong to?
Arcellx employs approximately 209 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
Financials
- EPS (TTM)
- -4.055
- Revenue (TTM)
- $22.29M
- EBITDA (TTM)
- -$246.41M
- Free Cashflow (TTM)
- -$212.59M
Analyst Ratings
The price target is $115.00 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.
- Employees
- 209
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- ACLX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet